Emerging cephalosporin and multidrug-resistant gonorrhoea in Europe

Eurosurveillance

Volumn 19, Issue 45, 2014, Pages 1-5

  Cole, M J ^a   Spiteri, G ^b   Chisholm, S A ^b   Hoffmann, S ^c   Ison, C A ^a   Unemo, M ^d   Van de Laar, M ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

^c STATENS SERUM INSTITUT   (Denmark)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; SPECTINOMYCIN;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; GEOGRAPHIC DISTRIBUTION; GONORRHEA; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEISSERIA GONORRHOEAE; NONHUMAN;

EID: 84924763763     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.es2014.19.45.20955     Document Type: Article

References (18)

1. Lewis DA. The Gonococcus fights back: is this time a knock out? Sex Transm Infect. 2010;86(6):415-21. http://dx.doi. org/10.1136/sti.2010.042648
2. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587-613. http://dx.doi. org/10.1128/CMR.00010-14
3. Van de Laar M, Spiteri G. Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe. Euro Surveill. 2012;17(29):pii=20225.
4. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol. 2012;7(12):1401-22. http://dx.doi.org/10.2217/ fmb.12.117
5. Lewis DA, Sriruttan C, Muller EE, Golparian D, Gumede L, Fick D, et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporinresistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother. 2013;68(6):1267-70. http://dx.doi.org/10.1093/jac/ dkt034
6. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA. 2013;309(2):163-70. http://dx.doi.org/10.1001/ jama.2012.176575
7. Bignell C, Unemo M, on behalf of the European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24(2):85-92. http://dx.doi. org/10.1177/0956462412472837
8. Cole MJ, Unemo M, Hoffmann S, Chisholm SA, Ison CA, van de Laar MJ. The European gonococcal antimicrobial surveillance programme, 2009. Euro Surveill. 2011;16(42):pii=19995.
9. European Centre for Disease Prevention and Control (ECDC). Response plan to control and manage the threat of multidrugresistant gonorrhoea in Europe. Stockholm: ECDC; 2012. Available from: http://ecdc.europa.eu/en/publications/ Publications/1206-ECDC-MDR-gonorrhoea-response-plan.pdf
10. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug- and extensively drugresistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther. 2009;7(7):821-34. http://dx.doi.org/10.1586/eri.09.63
11. European Centre for Disease Prevention and Control (ECDC). Gonococcal antimicrobial susceptibility surveillance in Europe 2011. Stockholm: ECDC; 2013. Available from: http://www. ecdc.europa.eu/en/publications/publications/gonococcalantimicrobial- susceptibility-surveillance-27-mar-2013.pdf
12. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Vaxjo : EUCAST; 2012. Available from: http:// www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/ Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf
13. Deguchi T, Yasuda M, Yokoi S, Ishida K, Ito M, Ishihara S, et al. Treatment of uncomplicated gonococcal urethritis by doubledosing of 200 mg cefixime at a 6-h interval. J Infect Chemother. 2003;9(1):35-9. http://dx.doi.org/10.1007/s10156-002-0204-8
14. Tapsall J. Antimicrobial resistance in Neisseria gonorrhoeae. Geneva: World Health Organization; 2001. Available from: http://www.who.int/drugresistance/Antimicrobial_resistance_ in_Neisseria_gonorrhoeae.pdf
15. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect. 2012;88(8):589-94. http://dx.doi. org/10.1136/sextrans-2012-050604
16. Chisholm SA, Quaye N, Cole MJ, Fredlund H, Hoffmann S, Jensen JS, et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother. 2011;66(3):592-5. http://dx.doi.org/10.1093/jac/ dkq476
17. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis. 1995;22(1):39-47. http://dx.doi. org/10.1097/00007435-199501000-00007
18. Ndowa F, Lusti-Narasimhan M, Unemo M. The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health. Sex Transm Infect. 2012;88(5):317-8. http://dx.doi. org/10.1136/sextrans-2012-050674